Supplementary Table 10 from Combination of Itacitinib or Parsaclisib with Pembrolizumab in Patients with Advanced Solid Tumors: A Phase I Study
Publication
, Other
Munster, P; Iannotti, N; Cho, DC; Kirkwood, JM; Villaruz, LC; Gibney, GT; Hodi, FS; Mettu, NB; Jones, M; Bowman, J; Smith, M; O'Day, S ...
December 19, 2023
Duke Scholars
Citation
APA
Chicago
ICMJE
MLA
NLM
Munster, P., Iannotti, N., Cho, D. C., Kirkwood, J. M., Villaruz, L. C., Gibney, G. T., … O’Day, S. (2023). Supplementary Table 10 from Combination of Itacitinib or Parsaclisib with Pembrolizumab in Patients with Advanced Solid Tumors: A Phase I Study. https://doi.org/10.1158/2767-9764.24866744.v1
Munster, Pamela, Nicholas Iannotti, Daniel C. Cho, John M. Kirkwood, Liza C. Villaruz, Geoffrey T. Gibney, F Stephen Hodi, et al. “Supplementary Table 10 from Combination of Itacitinib or Parsaclisib with Pembrolizumab in Patients with Advanced Solid Tumors: A Phase I Study,” December 19, 2023. https://doi.org/10.1158/2767-9764.24866744.v1.
Munster P, Iannotti N, Cho DC, Kirkwood JM, Villaruz LC, Gibney GT, et al. Supplementary Table 10 from Combination of Itacitinib or Parsaclisib with Pembrolizumab in Patients with Advanced Solid Tumors: A Phase I Study. 2023.
Munster, Pamela, et al. Supplementary Table 10 from Combination of Itacitinib or Parsaclisib with Pembrolizumab in Patients with Advanced Solid Tumors: A Phase I Study. 19 Dec. 2023. Crossref, doi:10.1158/2767-9764.24866744.v1.
Munster P, Iannotti N, Cho DC, Kirkwood JM, Villaruz LC, Gibney GT, Hodi FS, Mettu NB, Jones M, Bowman J, Smith M, Lakshminarayanan M, O’Day S. Supplementary Table 10 from Combination of Itacitinib or Parsaclisib with Pembrolizumab in Patients with Advanced Solid Tumors: A Phase I Study. 2023.